Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/186068
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mostaza, José María | - |
dc.contributor.author | Suarez, Carmen | - |
dc.contributor.author | Cepeda Rodrigo, José María | - |
dc.contributor.author | Manzano Espinosa, Luis | - |
dc.contributor.author | Sánchez, Demetrio | - |
dc.contributor.author | Fernández-Solà, J. (Joaquim) | - |
dc.contributor.author | PERFILAR study investigators | - |
dc.date.accessioned | 2022-05-27T18:21:19Z | - |
dc.date.available | 2022-05-27T18:21:19Z | - |
dc.date.issued | 2021-08-09 | - |
dc.identifier.issn | 1471-2261 | - |
dc.identifier.uri | http://hdl.handle.net/2445/186068 | - |
dc.description.abstract | Background This study assessed the sociodemographic, functional, and clinical determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation (NVAF) attended in the internal medicine setting. Methods A multicenter, cross-sectional study was conducted in NVAF patients who attended internal medicine departments for either a routine visit (outpatients) or hospitalization (inpatients). Results A total of 961 patients were evaluated. Their antithrombotic management included: no treatment (4.7%), vitamin K antagonists (VKAs) (59.6%), direct oral anticoagulants (DOACs) (21.6%), antiplatelets (6.6%), and antiplatelets plus anticoagulants (7.5%). Permanent NVAF and congestive heart failure were associated with preferential use of oral anticoagulation over antiplatelets, while intermediate-to high-mortality risk according to the PROFUND index was associated with a higher likelihood of using antiplatelet therapy instead of oral anticoagulation. Longer disease duration and institutionalization were identified as determinants of VKA use over DOACs. Female gender, higher education, and having suffered a stroke determined a preferential use of DOACs. Conclusions This real-world study showed that most elderly NVAF patients received oral anticoagulation, mainly VKAs, while DOACs remained underused. Antiplatelets were still offered to a proportion of patients. Longer duration of NVAF and institutionalization were identified as determinants of VKA use over DOACs. A poor prognosis according to the PROFUND index was identified as a factor preventing the use of oral anticoagulation. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s12872-021-02019-0 | - |
dc.relation.ispartof | BMC Cardiovascular Disorders, 2021, vol. 21, num. 1, p. 384 | - |
dc.relation.uri | https://doi.org/10.1186/s12872-021-02019-0 | - |
dc.rights | cc-by (c) Mostaza, José María et al., 2021 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Fibril·lació auricular | - |
dc.subject.classification | Trombosi | - |
dc.subject.classification | Fibrinolítics | - |
dc.subject.classification | Anticoagulants (Medicina) | - |
dc.subject.classification | Vitamines K | - |
dc.subject.other | Atrial fibrillation | - |
dc.subject.other | Thrombosis | - |
dc.subject.other | Fibrinolytic agents | - |
dc.subject.other | Anticoagulants (Medicine) | - |
dc.subject.other | Vitamin K | - |
dc.title | Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 718523 | - |
dc.date.updated | 2022-05-27T18:21:19Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34372782 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
718523.pdf | 870.21 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License